Skip to main content

Yesterday, May 23, 2016, 103 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $126.00 to $24,869,360.00.

Highlighted Stocks Traded by Insiders:

Wayfair (W) - FREE Research Report

Harbourvest Partners 2007 Direct Associates L.P., who is Shareholder at Wayfair, sold 136,200 shares at $40.35 on May 23, 2016. Following this transaction, the Shareholder owned 32,460 shares meaning that the stake was reduced by 80.75% with the 136,200-share transaction.

The shares most recently traded at $39.75, down $0.60, or 1.5% since the insider transaction. Historical insider transactions for Wayfair go as follows:

  • 4-Week # shares bought: 7,000
  • 4-Week # shares sold: 12,190
  • 12-Week # shares bought: 7,000
  • 12-Week # shares sold: 358,567
  • 24-Week # shares bought: 7,000
  • 24-Week # shares sold: 544,708

The average volume for Wayfair has been 1.2 million shares per day over the past 30 days. Wayfair has a market cap of $3.4 billion and is part of the services sector and retail industry. Shares are down 14.13% year-to-date as of the close of trading on Monday.

Wayfair Inc. engages in the e-commerce business in the United States. It offers approximately seven million products for the home under various brands. Currently, there are 6 analysts who rate Wayfair a buy, no analysts rate it a sell, and 7 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on W - FREE

TheStreet Quant Ratings

rates Wayfair as a

TheStreet Recommends

sell

. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, poor profit margins, weak operating cash flow and feeble growth in its earnings per share. Get the full

Wayfair Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Karyopharm Therapeutics (KPTI) - FREE Research Report

Chione Ltd, who is 10% Owner at Karyopharm Therapeutics, sold 93,932 shares at $8.54 on May 23, 2016. Following this transaction, the 10% Owner owned 8.8 million shares meaning that the stake was reduced by 1.06% with the 93,932-share transaction.

The shares most recently traded at $9.15, up $0.61, or 6.71% since the insider transaction. Historical insider transactions for Karyopharm Therapeutics go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 106,068
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 106,068
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 110,330

The average volume for Karyopharm Therapeutics has been 233,100 shares per day over the past 30 days. Karyopharm Therapeutics has a market cap of $308.9 million and is part of the health care sector and drugs industry. Shares are down 34.34% year-to-date as of the close of trading on Monday.

Karyopharm Therapeutics Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Currently, there are 3 analysts who rate Karyopharm Therapeutics a buy, 1 analyst rates it a sell, and 1 rates it a hold.

Exclusive Offer: Get the latest Stock Analysis on KPTI - FREE

TheStreet Quant Ratings

rates Karyopharm Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins, generally disappointing historical performance in the stock itself and deteriorating net income. Get the full

Karyopharm Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

GSE Systems (GVP) - FREE Research Report

Pugh Daniel Warren, who is SVP, General Counsel & RMO at GSE Systems, bought 5,000 shares at $2.19 on May 23, 2016. Following this transaction, the SVP, General Counsel & RMO owned 5,000 shares meaning that the stake was boosted by 100% with the 5,000-share transaction.

The shares most recently traded at $2.08, down $0.11, or 5.29% since the insider transaction. Historical insider transactions for GSE Systems go as follows:

  • 4-Week # shares bought: 30,900
  • 12-Week # shares bought: 30,900
  • 12-Week # shares sold: 10,000
  • 24-Week # shares bought: 63,900
  • 24-Week # shares sold: 10,000

The average volume for GSE Systems has been 32,800 shares per day over the past 30 days. GSE Systems has a market cap of $38.4 million and is part of the technology sector and computer software & services industry. Shares are down 13.75% year-to-date as of the close of trading on Monday.

GSE Systems, Inc. provides simulation, engineering, and training solutions and services to the nuclear and fossil power generation, oil and gas, refining, chemicals, petrochemicals, industrial gas, manufacturing, and plant utilities markets worldwide. Currently, there are no analysts who rate GSE Systems a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on GVP - FREE

TheStreet Quant Ratings

rates GSE Systems as a

sell

. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and poor profit margins. Get the full

GSE Systems Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.